1-(2-chloro-5-methylpyrimidin-4-yl)-4-methyl-1H-pyrrol-3-aldehyde | 1307803-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(2-chloro-5-methylpyrimidin-4-yl)-4-methyl-1H-pyrrol-3-aldehyde
• 英文别名: 1-(2-Chloro-5-methylpyrimidin-4-yl)-4-methylpyrrole-3-carbaldehyde
• CAS: 1307803-08-2
• 化学式: C₁₁H₁₀ClN₃O
• 分子量: 235.673
• InChiKey: ZVNHHQPTAHPQFU-UHFFFAOYSA-N

物化性质

• 沸点：
  446.4±45.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-羟乙基哌嗪 、 1-(2-chloro-5-methylpyrimidin-4-yl)-4-methyl-1H-pyrrol-3-aldehyde 在 triacetoxy sodium borohydride 作用下， 以 二氯甲烷 为溶剂， 反应 3.33h， 以91%的产率得到2-(4-((1-(2-chloro-5-methylpyrimidin-4-yl)-4-methyl-1H-pyrrol-3-yl)methyl)piperazin-1-yl)ethanol
  参考文献：
  名称：

  [EN] KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASES

  摘要：

  公开号：

  WO2011060295A8
• 作为产物：
  描述：

  在 manganese(IV) oxide 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 4.0h， 以87%的产率得到1-(2-chloro-5-methylpyrimidin-4-yl)-4-methyl-1H-pyrrol-3-aldehyde
  参考文献：
  名称：

  [EN] KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASES

  摘要：

  公开号：

  WO2011060295A8

文献信息

• COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES
  申请人：Yuhan Corporation

  公开号：US20160102076A1

  公开（公告）日：2016-04-14

  The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

  本发明提供了一类新的蛋白激酶抑制剂，氨基嘧啶衍生物及其药用可接受的盐，用于治疗细胞增殖性疾病和紊乱，如癌症和免疫疾病。本发明提供了合成和给药蛋白激酶抑制剂化合物的方法。本发明还提供了包含至少一种蛋白激酶抑制剂化合物的药物配方，以及药用可接受的载体、稀释剂或辅料。该发明还提供了在合成氨基嘧啶衍生物过程中产生的有用中间体。
• Kinase Inhibitors
  申请人：Lee Jaekyoo

  公开号：US20110281841A1

  公开（公告）日：2011-11-17

  The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.

  本发明提供了一种新的蛋白激酶抑制剂群，包括吡咯嘧啶和吡唑嘧啶衍生物，以及其药学上可接受的盐和前药，用于治疗细胞增殖性疾病和疾病，例如癌症、自身免疫性疾病、感染、心血管疾病和神经退行性疾病。本发明提供了合成和给药蛋白激酶抑制剂化合物的方法。本发明还提供了包含至少一种蛋白激酶抑制剂化合物和药学上可接受的载体、稀释剂或赋形剂的制剂。本发明还提供了在合成吡咯嘧啶和吡唑嘧啶衍生物的过程中产生的有用中间体。
• US8629132B2
  申请人：——

  公开号：US8629132B2

  公开（公告）日：2014-01-14
• US9593098B2
  申请人：——

  公开号：US9593098B2

  公开（公告）日：2017-03-14
• [EN] COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS À MODULER LES ACTIVITÉS KINASE DE L'EGFR MUTANT
  申请人：YUHAN CORP

  公开号：WO2016060443A2

  公开（公告）日：2016-04-21

  The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.